FDA user fee reauthorization linked to agency management changes by Rep. Barton.
This article was originally published in The Tan Sheet
Executive Summary
FDA USER FEE REAUTHORIZATION LINKED TO MANAGEMENT CHANGES BY REP. BARTON, which the House Commerce/Oversight Subcommittee chairman continues to view as a higher priority than reauthorization of user fees. During an April 23 Commerce/Health Subcommittee hearing on FDA, Rep. Joseph Barton (R-Tex.) maintained that his concerns may preclude his support of reauthorization of the Prescription Drug User Fee Act. "The record in my opinion doesn't justify continued authorization of PDUFA and unless we get some serious management reforms this summer, I probably will not support PDUFA reauthorization," Barton concluded.